Commit Biologics raises $60 million in seed financing with M Ventures participation

By Public Technologies
  • Commit Biologics completed a $60 million (€54 million) seed financing round on November 17, 2026, with participation from M Ventures.
  • Ackermans & van Haaren led the final close, with AbbVie Ventures also joining as a new investor.
  • The biotechnology company develops complement-powered immune engagers for cancer and autoimmune diseases.
  • Proceeds will take lead candidate COM002 toward clinical development, advance a second program into IND-enabling development and expand the pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck Ventures BV published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk